Arcellx Financials
| ACLX Stock | USD 69.87 2.87 3.95% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.34 | 4.779 |
|
|
Investors should never underestimate Arcellx's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Arcellx's cash flow, debt, and profitability to make informed and accurate decisions about investing in Arcellx.
Net Income |
|
Arcellx | Select Account or Indicator |
Understanding current and past Arcellx Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Arcellx's financial statements are interrelated, with each one affecting the others. For example, an increase in Arcellx's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Arcellx's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Arcellx. Check Arcellx's Beneish M Score to see the likelihood of Arcellx's management manipulating its earnings.
Arcellx Stock Summary
Arcellx competes with Nuvalent, Ventyx Biosciences, Amylyx Pharmaceuticals, Day One, and Biomea Fusion. Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland. Arcellx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 78 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US03940C1009 |
| CUSIP | 03940C100 |
| Location | Maryland; U.S.A |
| Business Address | 800 Bridge Parkway, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.arcellx.com |
| Phone | 240 327 0630 |
| Currency | USD - US Dollar |
Arcellx Key Financial Ratios
| Return On Equity | -0.23 | ||||
| Profit Margin | (0.99) % | ||||
| Operating Margin | (3.48) % | ||||
| Price To Sales | 37.03 X | ||||
| Revenue | 107.94 M |
Arcellx Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Net Tangible Assets | (32.7M) | (63.7M) | (121.5M) | 205.0M | 235.7M | 247.5M | |
| Retained Earnings | (65.1M) | (130.1M) | (318.8M) | (389.5M) | (496.8M) | (472.0M) | |
| Accounts Payable | 504K | 1.3M | 9.1M | 2.6M | 2.1M | 2.9M | |
| Other Assets | 3.4M | 5.7M | 7.1M | 1.0 | 1.15 | 1.09 | |
| Total Current Assets | 49.4M | 112.8M | 266.9M | 716.4M | 599.3M | 629.3M | |
| Total Assets | 57.7M | 128.8M | 313.8M | 825.1M | 711.3M | 381.4M | |
| Other Current Liab | 4.8M | 13.5M | 11.7M | 18.3M | 56.7M | 59.6M | |
| Net Debt | (46.6M) | (104.5M) | 24.0M | (297.0M) | (51.6M) | (54.2M) | |
| Cash | 46.6M | 104.6M | 64.2M | 394.6M | 104.6M | 137.3M | |
| Other Current Assets | 2.8M | 8.2M | 12.0M | 14.3M | 11.9M | 9.1M | |
| Total Liab | 121.4M | 250.3M | 108.9M | 339.8M | 256.5M | 211.4M | |
| Net Invested Capital | (63.7M) | (121.5M) | 205.0M | 485.4M | 454.8M | 477.5M | |
| Net Working Capital | 44.1M | 98.0M | 210.2M | 598.1M | 473.9M | 267.5M |
Arcellx Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Ebit | (32.1M) | (65.0M) | (187.0M) | (66.2M) | (104.2M) | (109.5M) | |
| Gross Profit | (629K) | (1.0M) | (2.2M) | 110.3M | 107.9M | 113.3M | |
| Operating Income | (32.1M) | (65.0M) | (191.3M) | (89.9M) | (137.6M) | (144.4M) | |
| Research Development | 25.1M | 46.9M | 149.6M | 133.8M | 157.1M | 96.8M | |
| Ebitda | (31.5M) | (64.0M) | (184.7M) | (64.1M) | (99.1M) | (104.0M) | |
| Cost Of Revenue | 629K | 1.0M | 2.2M | 2.0M | 2.3M | 1.4M | |
| Income Before Tax | (32.1M) | (65.0M) | (188.7M) | (70.0M) | (105.3M) | (110.5M) | |
| Net Income | (32.1M) | (63.9M) | (186.1M) | (70.7M) | (107.3M) | (112.7M) | |
| Income Tax Expense | 422.7K | (1.0M) | (2.6M) | 663K | 2.1M | 2.2M |
Arcellx Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Arcellx's current stock value. Our valuation model uses many indicators to compare Arcellx value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Arcellx competition to find correlations between indicators driving Arcellx's intrinsic value. More Info.Arcellx is rated second in return on equity category among its peers. It is number one stock in return on asset category among its peers . At this time, Arcellx's Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Arcellx's earnings, one of the primary drivers of an investment's value.Arcellx Systematic Risk
Arcellx's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Arcellx volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on Arcellx correlated with the market. If Beta is less than 0 Arcellx generally moves in the opposite direction as compared to the market. If Arcellx Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Arcellx is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Arcellx is generally in the same direction as the market. If Beta > 1 Arcellx moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Arcellx Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Arcellx's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Arcellx growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Arcellx March 19, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Arcellx help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Arcellx. We use our internally-developed statistical techniques to arrive at the intrinsic value of Arcellx based on widely used predictive technical indicators. In general, we focus on analyzing Arcellx Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Arcellx's daily price indicators and compare them against related drivers.
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 13.77 | |||
| Value At Risk | (5.21) | |||
| Potential Upside | 4.95 |
Additional Tools for Arcellx Stock Analysis
When running Arcellx's price analysis, check to measure Arcellx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcellx is operating at the current time. Most of Arcellx's value examination focuses on studying past and present price action to predict the probability of Arcellx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcellx's price. Additionally, you may evaluate how the addition of Arcellx to your portfolios can decrease your overall portfolio volatility.